Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.
Popularity: unranked [?]
Central Nervous System Fibromyalgia Industry News
Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia
Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.
Popularity: unranked [?]
